Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Neurofibromatosis: early-phase trial registry

2 of 6 indexed Neurofibromatosis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Neurofibromatosis: 6 US clinical trials tracked, 2 recruiting.

Neurofibromatosis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.

Enrollment posture brief

Registry condition neurofibromatosis

OPEN 2 | RECR 33% | LATE 0 | EARLY 3 | RANK #2866 | SPON 2

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Neurofibromatosis (this)33%
Open-enrollment share among volume-matched conditions near Neurofibromatosis

Neurofibromatosis lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neurofibromatosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neurofibromatosis is recruiting below its size-band peers.

    2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Neurofibromatosis research.

    National Cancer Institute (NCI) accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Neurofibromatosis trials plan to enrol fewer than 100 people.

    Median target enrolment is 61 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Neurofibromatosis splits between interventional and observational designs.

    3 interventional and 3 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1

Named interventions

Most-linked intervention names on Neurofibromatosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

[18F]-FLT-PET/CT scans Drug
1 trials
MRI, FDG-PET/CT scans Procedure
1 trials
Imlygic Drug
1 trials
Questionnaire Behavioral
1 trials
Cabozantinib Drug
1 trials

US sites by state

Facility locations filed on Neurofibromatosis trials. A trial with sites in several states counts in each.

Maryland 5 trials
Utah 1 trials
Texas 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
Missouri 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neurofibromatosis page

6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurofibromatosis condition card totals 6 registered trials; most-linked intervention [18F]-FLT-PET/CT scans; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.